AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22330010 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 50
Study 20141299 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT) for 8 weeks
Number of subjects: 0
Study 20141299 — intervention group
Group type: COMPARATOR
Intervention: Waitlisted controls
Number of subjects: 0
Study 18525491 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-level kyphoplasty
Number of subjects: 27
Study 18525491 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 or 3-level kyphoplasty
Number of subjects: 27
Study 16002829 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-protein diets
Number of subjects: 0
Study 16002829 — intervention group
Group type: COMPARATOR
Intervention: Lower-protein diets
Number of subjects: 0
Study 16002829 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased protein intake
Number of subjects: 0
Study 12443525 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurophysiological facilitation
Number of subjects: 13
Study 12443525 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive movement
Number of subjects: 13
Study 12443525 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory stimulation
Number of subjects: 13
Study 12443525 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 13
Study 10513865 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (2.0 mL = 4.0 mg)
Number of subjects: 50
Study 10513865 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (2.0 mL)
Number of subjects: 50
Study 7725371 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic approach to individualizing phenytoin dose based on one-point, steady-state plasma concentration
Number of subjects: 35
Study 2143960 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide + Hydrocortisone (AG + HC)
Number of subjects: 59
Study 2143960 — intervention group
Group type: COMPARATOR
Intervention: Medroxyprogesterone Acetate + Hydrocortisone (MPA + HC)
Number of subjects: 59
Study 6156412 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g i.v. gammaglobulin (Intraglobin)
Number of subjects: 150
Study 6156412 — intervention group
Group type: COMPARATOR
Intervention: Control group (without gammaglobulin)
Number of subjects: 150
Study 29514847 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumer-driven product materials provided at the point of sale
Number of subjects: 836
Study 29514847 — intervention group
Group type: COMPARATOR
Intervention: Standard information provided at the point of sale (Control)
Number of subjects: 836
Study 28941144 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP levels in HFrEF patients
Number of subjects: 288
Study 28941144 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP levels in HFrlEF patients
Number of subjects: 288
Study 28941144 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP levels in HFrhEF patients
Number of subjects: 288
Study 26953235 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with usual care (12-16 sessions of manual acupuncture±electroacupuncture over 6 weeks)
Number of subjects: 50
Study 26953235 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone (control group)
Number of subjects: 50
Study 26953235 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with usual care
Number of subjects: 50
Study 23864286 — intervention group
Group type: COMPARATOR
Intervention: Training experienced anatomy teachers in the use of the one-minute preceptor (OMP) technique.
Number of subjects: 152
Study 23864286 — intervention group
Group type: COMPARATOR
Intervention: Experienced teachers' own approaches (not using OMP).
Number of subjects: 152
Study 23141074 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual-to-auditory sensory-substitution algorithm (soundscapes)
Number of subjects: 0
Study 20496567 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin regimen (28 daily doses of rifampicin 600mg + ofloxacin 400mg + 5 months placebo)
Number of subjects: 124
Study 20496567 — intervention group
Group type: COMPARATOR
Intervention: Standard WHO-MDT regimen (6-month treatment)
Number of subjects: 124
Study 18031971 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional care by a pulmonary nurse (protocol‐based education program, average duration 60 min per patient)
Number of subjects: 191
Study 18031971 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 191
Study 15975149 — intervention group
Group type: EXPERIMENTAL
Intervention: CD14 -159CC genotype
Number of subjects: 45
Study 15975149 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma sCD14 levels
Number of subjects: 45
Study 12582353 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancellous cores (CC) harvested through a 0.5- to 1.0-cm incision with a motor-driven trephine
Number of subjects: 76
Study 12582353 — intervention group
Group type: COMPARATOR
Intervention: Corticocancellous block grafts (CCBG) harvested by traditional open medial approach
Number of subjects: 76
Study 10749335 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 megaunits (MU) of human lymphoblastoid IFN six days per week for two weeks, followed by three days per week for 50 weeks
Number of subjects: 35
Study 10749335 — intervention group
Group type: COMPARATOR
Intervention: 6 MU six days per week for two weeks followed by three days per week for 24 weeks
Number of subjects: 35
Study 8751521 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermia (n = 68)
Number of subjects: 138
Study 8751521 — intervention group
Group type: COMPARATOR
Intervention: Hypothermia (n = 70)
Number of subjects: 138
Study 8751521 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 138
Study 1431009 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg daily (increased at week 3 if necessary)
Number of subjects: 309
Study 1431009 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline 75 mg daily in divided doses (increased at week 3 if necessary)
Number of subjects: 309
Study 4034823 — intervention group
Group type: EXPERIMENTAL
Intervention: Covert positive reinforcement
Number of subjects: 80
Study 4034823 — intervention group
Group type: COMPARATOR
Intervention: Backward conditioning
Number of subjects: 80
Study 4034823 — intervention group
Group type: COMPARATOR
Intervention: Covert rehearsal
Number of subjects: 80
Study 4034823 — intervention group
Group type: COMPARATOR
Intervention: Expectancy conditions
Number of subjects: 80
Study 4034823 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-generated coping strategies
Number of subjects: 80
Study 30892294 — intervention group
Group type: EXPERIMENTAL
Intervention: 3Y-TZP (group A)
Number of subjects: 48
Study 30892294 — intervention group
Group type: EXPERIMENTAL
Intervention: 4Y-TZP (group B)
Number of subjects: 48
Study 30892294 — intervention group
Group type: EXPERIMENTAL
Intervention: 5Y-TZP (group C)
Number of subjects: 48
Study 28504315 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to a suicide news article with psychoeducational information and preventative resources
Number of subjects: 0
Study 28504315 — intervention group
Group type: COMPARATOR
Intervention: Exposure to a suicide news article without psychoeducational information and preventative resources
Number of subjects: 0
Study 27283370 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenotomy (group I)
Number of subjects: 128
Study 27283370 — intervention group
Group type: COMPARATOR
Intervention: Tenodesis (group II)
Number of subjects: 128
Study 24390800 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency surgery of the soft palate
Number of subjects: 35
Study 24390800 — intervention group
Group type: COMPARATOR
Intervention: Sham surgery of the soft palate
Number of subjects: 35
Study 23121473 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin + metformin
Number of subjects: 171
Study 23121473 — intervention group
Group type: COMPARATOR
Intervention: Placebo + metformin
Number of subjects: 171
Study 20099946 — intervention group
Group type: EXPERIMENTAL
Intervention: Past-year mood disorder
Number of subjects: 1504
Study 20099946 — intervention group
Group type: EXPERIMENTAL
Intervention: Ever diagnosed anxiety disorder
Number of subjects: 1504
Study 20099946 — intervention group
Group type: EXPERIMENTAL
Intervention: Ever diagnosed with more than one psychiatric diagnosis
Number of subjects: 1504
Study 20099946 — intervention group
Group type: COMPARATOR
Intervention: Never diagnosed group
Number of subjects: 1504
Study 18513646 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary bone marrow cell (BMC) transplantation (1 x 10^8 cells)
Number of subjects: 62
Study 18513646 — intervention group
Group type: COMPARATOR
Intervention: Control group (no BMC treatment)
Number of subjects: 62
Study 15742825 — intervention group
Group type: COMPARATOR
Intervention: Caffeine gum 0 mg (placebo)
Number of subjects: 9
Study 15742825 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine gum 100 mg (low dose)
Number of subjects: 9
Study 15742825 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine gum 300 mg (high dose)
Number of subjects: 9
Study 12095806 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim (160 mg)/sulfamethoxazole (800 mg) every 3 days (61 patients)
Number of subjects: 124
Study 12095806 — intervention group
Group type: COMPARATOR
Intervention: Observation without treatment (63 patients)
Number of subjects: 124
Study 9827404 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative thromboprophylaxis consensus
Number of subjects: 505
Study 9827404 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower than recommended heparin dosage
Number of subjects: 505
Study 9827404 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 505
Study 9827404 — intervention group
Group type: EXPERIMENTAL
Intervention: Age over 70 years
Number of subjects: 505
Study 9827404 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced mobility
Number of subjects: 505
Study 8018619 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5%
Number of subjects: 60
Study 8018619 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 60
Study 2684551 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release oral ketotifen (2 mg daily for 12 weeks)
Number of subjects: 245
Study 2684551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study 2684551 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release oral ketotifen
Number of subjects: 245
Study 1152627 — intervention group
Group type: EXPERIMENTAL
Intervention: Running (n = 9)
Number of subjects: 35
Study 1152627 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking (n = 9)
Number of subjects: 35
Study 1152627 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycling (n = 8)
Number of subjects: 35
Study 1152627 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 7)
Number of subjects: 35
Study 30004123 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/day n3‐PUFA
Number of subjects: 40
Study 30004123 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g/day n3‐PUFA
Number of subjects: 40
Study 30004123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 27824434 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine 266 mg/20 mL (admixed with standard bupivacaine 0.5% 20 mL)
Number of subjects: 0
Study 27824434 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5% 20 mL
Number of subjects: 0
Study 25391338 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 880
Study 25391338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 880
Study 22683226 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide 100 mg/day up-titrated to 300 mg/day
Number of subjects: 583
Study 22683226 — intervention group
Group type: COMPARATOR
Intervention: Controlled-release carbamazepine 200 mg/day up-titrated to 600 mg/day
Number of subjects: 583
Study 22683226 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide
Number of subjects: 583
Study 22683226 — intervention group
Group type: COMPARATOR
Intervention: Controlled-release carbamazepine
Number of subjects: 583
Study 20453627 — intervention group
Group type: EXPERIMENTAL
Intervention: DOT‐ART
Number of subjects: 274
Study 18822982 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with local blocking therapy
Number of subjects: 100
Study 18822982 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of 25 mg Indomethacin thrice daily and 100 mg Allopurinol thrice daily
Number of subjects: 100
Study 15621991 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapband
Number of subjects: 180
Study 15621991 — intervention group
Group type: COMPARATOR
Intervention: SAGB
Number of subjects: 180
Study 11865962 — intervention group
Group type: EXPERIMENTAL
Intervention: New intravenous varicella zoster immune globulin (VZIG)
Number of subjects: 57
Study 11865962 — intervention group
Group type: COMPARATOR
Intervention: Standard intramuscular varicella zoster immune globulin (VZIG)
Number of subjects: 57
Study 10526698 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers (lipophilic agents such as timolol, metoprolol, propranolol, bisoprolol, and carvedilol)
Number of subjects: 55000
Study 10526698 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers (lipophilic agents)
Number of subjects: 55000
Study 7839425 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-drug therapy (cyclosporine, azathioprine, and prednisolone)
Number of subjects: 34
Study 7839425 — intervention group
Group type: COMPARATOR
Intervention: Double-drug therapy (azathioprine and prednisolone)
Number of subjects: 34
Study 7839425 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-drug to double-drug therapy conversion
Number of subjects: 34
Study 2495049 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (20 mg three times daily for the first month, then 40 mg three times daily thereafter)
Number of subjects: 3899
Study 2495049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3899
Study 2495049 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (after excluding patients taking potassium losing diuretics)
Number of subjects: 3899
Study 2495049 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after excluding patients taking potassium losing diuretics)
Number of subjects: 3899
Study 605770 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 107
Study 605770 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 107
Study 605770 — intervention group
Group type: EXPERIMENTAL
Intervention: Both
Number of subjects: 107
Study 7043304 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol 300 mg I/ml
Number of subjects: 27
Study 7043304 — intervention group
Group type: COMPARATOR
Intervention: Conray meglumine 282 mg I/ml
Number of subjects: 27
Study 7043304 — intervention group
Group type: COMPARATOR
Intervention: Amipaque 300 mg I/ml
Number of subjects: 27
Study 31806484 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Reduction and Internal Fixation (ORIF)
Number of subjects: 40
Study 31806484 — intervention group
Group type: COMPARATOR
Intervention: Maxillo‐mandibular fixation (MMF)
Number of subjects: 40
Study 31420131 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot-support
Number of subjects: 19
Study 31420131 — intervention group
Group type: COMPARATOR
Intervention: Forward tilted seating (FW)
Number of subjects: 19
Study 31420131 — intervention group
Group type: COMPARATOR
Intervention: Horizontal seat
Number of subjects: 19
Study 31420131 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot-support with horizontal seat
Number of subjects: 19
Study 30600733 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathology diagnosis of MC
Number of subjects: 211
Study 30600733 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathology diagnosis of collagenous colitis (CC)
Number of subjects: 211
Study 30600733 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathology diagnosis of lymphocytic colitis (LC)
Number of subjects: 211
Study 30600733 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of MC
Number of subjects: 211
Study 30600733 — intervention group
Group type: EXPERIMENTAL
Intervention: Stool culture
Number of subjects: 211
Study 30600733 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiac serology
Number of subjects: 211
Study 30600733 — intervention group
Group type: EXPERIMENTAL
Intervention: Other autoimmune diseases
Number of subjects: 211
Study 29282954 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacrococcygeal massage therapy, 3 times a week for 2 weeks
Number of subjects: 184
Study 29282954 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac Diethylamine Emulgel, 2 times a day for 2 weeks
Number of subjects: 184
Study 25218839 — intervention group
Group type: EXPERIMENTAL
Intervention: Riata patients
Number of subjects: 299
Study 25218839 — intervention group
Group type: COMPARATOR
Intervention: Nonadvisory controls
Number of subjects: 299
Study 22050449 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg once daily) plus sodium alginate (30 mL four times a day)
Number of subjects: 76
Study 22050449 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (20 mg once daily) alone
Number of subjects: 76
Study 18836704 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 microg CCK‐8S
Number of subjects: 64
Study 18836704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 17505072 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium clodronate (2080 mg/day)
Number of subjects: 508
Study 17505072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 508
Study 14871425 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0
Study 14871425 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 0
Study 14871425 — intervention group
Group type: EXPERIMENTAL
Intervention: SUA as a time-varying covariate
Number of subjects: 0
Study 14871425 — intervention group
Group type: EXPERIMENTAL
Intervention: SUA in women
Number of subjects: 0
Study 14871425 — intervention group
Group type: EXPERIMENTAL
Intervention: SUA in men
Number of subjects: 0
Study 14871425 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment effect of losartan on primary composite endpoint
Number of subjects: 0
Study 12397463 — intervention group
Group type: COMPARATOR
Intervention: FTD patients (n=8)
Number of subjects: 29
Study 12397463 — intervention group
Group type: EXPERIMENTAL
Intervention: AD patients (n=21)
Number of subjects: 29
Study 9836031 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 7.5% in nitrous oxide 67% in oxygen
Number of subjects: 67
Study 9836031 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane 3.5% in nitrous oxide 67% in oxygen
Number of subjects: 67
Study 8021761 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant IFN-alpha (3 million units per square meter of body surface area, three times a week for 15 months)
Number of subjects: 65
Study 8021761 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated subjects)
Number of subjects: 65
Study 8021761 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant IFN-alpha
Number of subjects: 65
Study 2920318 — intervention group
Group type: COMPARATOR
Intervention: Latex catheter
Number of subjects: 100
Study 2920318 — intervention group
Group type: COMPARATOR
Intervention: Silicone catheter
Number of subjects: 100
Study 2920318 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed urinary drainage system with strict sterile conditions and meticulous ongoing catheter care
Number of subjects: 100
Study 1101758 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 80
Study 1101758 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 80
Study 30472902 — intervention group
Group type: EXPERIMENTAL
Intervention: CLM‐L tablets
Number of subjects: 0
Study 30472902 — intervention group
Group type: COMPARATOR
Intervention: Immediate release CLM tablets
Number of subjects: 0
Study 28109266 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-based care (TBC) intervention conducted by an interprofessional team (nurse, community pharmacist, physician) with sessions every 6 weeks for 6 months.
Number of subjects: 110
Study 28109266 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) without sessions with a nurse and a pharmacist.
Number of subjects: 110
Study 28109266 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-based care (TBC) intervention
Number of subjects: 110
Study 28109266 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 110
Study 26516910 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 microgram menaquinone-7 (MK-7) supplementation for 24 months
Number of subjects: 0
Study 26516910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23786783 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta 44 μg subcutaneously 3 times weekly
Number of subjects: 19
Study 23786783 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate 20 mg subcutaneously once weekly
Number of subjects: 19
Study 22030782 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral immunonutrition group (n=53)
Number of subjects: 106
Study 20067113 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (0.2 g, qd for 7 days before operation)
Number of subjects: 36
Study 20067113 — intervention group
Group type: COMPARATOR
Intervention: Control (no medication before resection)
Number of subjects: 36
Study 17182193 — intervention group
Group type: EXPERIMENTAL
Intervention: One hour additional sleep per night at baseline
Number of subjects: 500
Study 17182193 — intervention group
Group type: COMPARATOR
Intervention: Smoking status at follow-up
Number of subjects: 500
Study 17182193 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of cigarettes per day
Number of subjects: 500
Study 17182193 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessment of smoking behaviour in 5 years
Number of subjects: 500
Study 14747361 — intervention group
Group type: EXPERIMENTAL
Intervention: School Intervention Program (SIP)
Number of subjects: 24
Study 14747361 — intervention group
Group type: COMPARATOR
Intervention: Routine Services (RS)
Number of subjects: 24
Study 10376168 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac-potassium 50 mg
Number of subjects: 156
Study 10376168 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac-potassium 100 mg
Number of subjects: 156